These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 34817847)

  • 1. Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System.
    Bhardwaja B; Klocke S; Ekinci E; Jackson A; Kono S; Olson KL
    BioDrugs; 2022 Jan; 36(1):1-11. PubMed ID: 34817847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
    Mansell K; Bhimji H; Eurich D; Mansell H
    BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of the FDA Biosimilar Extrapolation Framework to Make Off-Label Determinations.
    Li E; Lobaina E
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1227-1232. PubMed ID: 29172978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel approach to support implementation of biosimilars within a UK tertiary hospital.
    Saxby K; Sanghvi S; Bodalia PN; Ferner RE; Leandro M; Urquhart R; Sofat R
    Br J Clin Pharmacol; 2020 Jan; 86(1):23-28. PubMed ID: 31663154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilar Use Among 38 ASCO PracticeNET Practices, 2019-2021.
    Bourbeau B; Lyman GH; Lei XJ; Jones L; Rosenthal J; Kozlik MM; Oettel KR; Tinger A; Page R
    JCO Oncol Pract; 2023 Jul; 19(7):516-522. PubMed ID: 37084324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019.
    Liu A; Xuan A; Socal M; Anderson G; Anderson KE
    J Manag Care Spec Pharm; 2024 Jan; 30(1):15-21. PubMed ID: 38153867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Tanni KA; Truong CB; Almahasis S; Qian J
    BioDrugs; 2021 Mar; 35(2):239-254. PubMed ID: 33439472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012-19.
    Chen HH; Yemeke T; Ozawa S
    PLoS One; 2024; 19(6):e0304851. PubMed ID: 38843282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness.
    Dutcher SK; Fazio-Eynullayeva E; Eworuke E; Carruth A; Dee EC; Blum MD; Nguyen MD; Toh S; Panozzo CA; Lyons JG
    Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):786-795. PubMed ID: 31828887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilar underutilization alone does not foretell a broken biologics market.
    LaMountain F; Beinfeld MT; Wong W; Kim E; Chambers JD
    Health Aff Sch; 2024 Jul; 2(7):qxae090. PubMed ID: 39071106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis.
    Na H; Kwon SH; Son KH; Baek Y; Kim J; Lee EK
    BioDrugs; 2023 Mar; 37(2):205-218. PubMed ID: 36729329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of the use of infliximab biosimilars in rheumatology and gastroenterology clinics.
    Steedman S; Giang J
    J Manag Care Spec Pharm; 2024 Jan; 30(1):22-25. PubMed ID: 38153865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage.
    Karaca-Mandic P; Chang J; Go R; Schondelmeyer S; Weisdorf D; Jeffery MM
    Health Aff (Millwood); 2019 Nov; 38(11):1887-1892. PubMed ID: 31682491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uptake of Biosimilar Among Privately Insured Patients Undergoing Infliximab Treatment.
    Chang J; Karaca-Mandic P; Jeffery MM
    Med Care; 2023 Oct; 61(10):636-643. PubMed ID: 37582298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review.
    Bakalos G; Zintzaras E
    Clin Ther; 2019 Jan; 41(1):155-173.e13. PubMed ID: 30551802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
    Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
    Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.